Literature DB >> 23096146

[Vitreomacular interface and posterior vitreomacular adhesion in exudative age-related macular degeneration (AMD): an OCT-based comparative study].

M Maier1, S Pfrommer, S Burzer, N Feucht, C Winkler von Mohrenfels, C P Lohmann.   

Abstract

PURPOSE: The aim of this study was to evaluate posterior vitreomacular adhesion as a risk factor for choroidal neovascularisation (CNV) in age-related macular degeneration (AMD). The vitreoretinal interface was examined using spectralis optical coherence tomography (Spectralis-OCT, Heidelberg Engineering). PATIENTS AND METHODS: In a retrospective observational case series 375 consecutive eyes of 375 patients (age 51-90 years) were examined with spectralis OCT and fluorescein angiography (Spectralis-HRA, Heidelberg Engineering). Vitreomacular adhesion was defined when a posterior hyaloid line attached to the inner retinal surface was seen in OCT. In 202 patients with exudative AMD the incidence of posterior vitreomacular adhesion was compared to 173 control eyes (72 with non-exudative AMD and 101 eyes without retinal alterations).
RESULTS: We found posterior vitreomacular adhesions in 151 patients (40.27 %). In the control group 53 patients (30.6 %) showed vitreomacular adhesions compared to 98 patients (48.5 %) with exudative AMD. The difference was statistically significant (p = 0.001). The location of vitreomacular adhesion was observed over the area of the CNV in 87 patients (88 %) with exudative AMD.
CONCLUSIONS: Spectralis OCT allows a detailed examination of the vitreomacular interface. The frequency of posterior vitreomacular adhesion is significantly increased in eyes with CNV in AMD. Chronic vitreomacular traction may be a risk factor for the development of exudative AMD. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2012        PMID: 23096146     DOI: 10.1055/s-0032-1315305

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  5 in total

1.  Spectrum of morphological and visual changes due to vitreomacular interface disorders encountered in a large consecutive cohort of patients.

Authors:  W Fusi-Rubiano; M Awad; R Manjunath; I Elaraoud; N Narendran; Y Yang
Journal:  Eye (Lond)       Date:  2015-01-09       Impact factor: 3.775

2.  Visual function response to ocriplasmin for the treatment of vitreomacular traction and macular hole.

Authors:  Timothy L Jackson; Thomas Verstraeten; Luc Duchateau; Benedicte Lescrauwaet
Journal:  Acta Ophthalmol       Date:  2017-01-30       Impact factor: 3.761

3.  Effects of Vitreomacular Traction on Ranibizumab Treatment Response in Eyes with Neovascular Age-related Macular Degeneration.

Authors:  Kang Hoon Lee; Hee Seung Chin; Na Rae Kim; Yeon Sung Moon
Journal:  Korean J Ophthalmol       Date:  2015-11-25

4.  AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: The ARI2 Study.

Authors:  Rocio Blanco-Garavito; Camille Jung; Joel Uzzan; Maddalena Quaranta-ElMaftouhi; Florence Coscas; Jose Sahel; Jean-Francois Korobelnik; Stéphane Béchet; Giuseppe Querques; Eric H Souied
Journal:  Retina       Date:  2018-12       Impact factor: 4.256

Review 5.  OCT Biomarkers in Neovascular Age-Related Macular Degeneration: A Narrative Review.

Authors:  Cristian Metrangolo; Simone Donati; Marco Mazzola; Liviana Fontanel; Walter Messina; Giulia D'alterio; Marisa Rubino; Paolo Radice; Elias Premi; Claudio Azzolini
Journal:  J Ophthalmol       Date:  2021-07-17       Impact factor: 1.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.